pharmeceutical company patent for cbd oil

Trends in intellectual property rights protection for medical cannabis and related products

The purpose of this review is to advance the field of applied cannabis research by providing insights into the patenting of medical cannabis and current intellectual property rights (IPR) data.

Medical cannabis (MC) patent and plant breeders’ rights (PBR) registrations are filed on industrially applicable aspects of research. Studying the filing data and trends informs researchers of both gaps in current applied knowledge in MC (where patents have not been filed) and prior knowledge (where patents have already been filed).

Our focus is on those intellectual property rights (IPR) that are registered and germane to technical innovations in MC and related products. These are patents and PBR and thus exclude trade secrets, copyrights, franchises, or trademarks. Methods used for surveying the defined IPR landscape include searches of publicly available patent and PBR data and classifying the data according to the upstream–midstream–downstream innovation paradigm of the MC industry.

The findings suggest that the technical knowledge as expressed by patent filings is growing commensurate to the economic and legislative activity. Specific cannabis patents in agricultural technologies directed at improving yield, efficiency, and quality (known as “agritech”) are being filed and granted. These agritech-focused patents represent original novel and applied MC research achievements that address specific problems in cannabis cultivation, such as protection of the cannabis crop, maximizing cannabis yield, harvesting and post-harvesting of cannabis, and new advantageous varieties. Patents on ex planta and in planta cannabis genes expression have been published in recent years while patents on extraction methods for cannabinoids have increased since 2015. Much patent activity is in the downstream category of MC patient-oriented products and delivery systems for a very wide range of medical indications and disease conditions.

The emerging importance of access and benefit-sharing treaties and regulations is noted with implications on the industry briefly discussed. Patent data on leading and emerging patentee companies and institutions are shown. We also provide evidence of prior art and freedom to operate.

Background

Medical cannabis (MC) or medical marijuana is defined herein as those products prescribed by physicians for patient therapy. There is no agreed definition of medicinal cannabis. The term is often used to refer to the therapeutic use of herbal cannabis and its constituents (Whiting et al. 2015). The cannabis plant contains more than 100 different chemicals, known as cannabinoids. Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the main relevant chemicals used in medicine (Bridgeman and Abazia 2017). THC produces the “high” that people feel when they smoke marijuana or eat foodstuffs containing it. The number of patients receiving medical cannabis products in the USA is estimated at over 3,000,000, with physicians in other countries such as the UK, Europe, Canada, Israel, and Australia increasingly prescribing MC to their patients (Number of Legal Medical Marijuana Patients – Medical Marijuana n.d.).

MC compounds emerge from processing beginning with a cultivated plant to a natural product (“plant-to-drug”), rather than a pharmaceutically synthesized molecule. Thus, the nascent MC industry has product pathways that sharply differ from the mainstream pharmaceutical industry.

MC-related matters are complicated in that, in almost all countries, cannabis is an illegal drug and is subject to legal constraints at the national and international level.

Although the geographical, historical, and cultural ubiquity of cannabis products has been described, knowledge surrounding the origins of cannabis use in folklore medicine is still vague (Heilig 2011; Zlas et al. 1993; Kuddus et al. 2013; Ren et al. 2019; West n.d.). In spite of the fact that cannabis has been used for centuries, the rigor demanded by present day regulatory authorities and modern medical standards raises particular challenges not often encountered in classical pharmaceutics based on defined single molecules.

These difficulties notwithstanding, MC companies must obtain governmental approval for specific indications if MC products are to enjoy the potential profits unlocked by manufacturing and distributing a novel approved medical product, influencing the scope and feasibility of cannabis drug development.

As MC use gains greater credibility, the market has come under constant and growing scrutiny from many stakeholders, including patient groups, physicians, research teams, companies, investors, government agencies, business analysts, lawyers, and Intellectual Property (IP) specialists. Much statistical information on MC is now routinely available and widely reported, some of which is introduced in this review.

The National Institutes of Health (NIH) reports 162 clinical trials on cannabis-based drugs overall (Search of: cannabis or cannabinoid or marijuana – List Results n.d.) with 58 clinical trials listed in the European Union Clinical Trials Register (Clinical Trials register – Search for Cannabis n.d.).

In 2018, the medical cannabis market was estimated at about 13.4 billion USD and is expected to reach 66.3 billion USD by 2025 with a compound annual growth rate (CAGR) of 22.9% from 2019 to 2025 (Medical Cannabis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024 n.d.). The North American Medical Marijuana index (founded in 2015) has already documented 49 companies with a total market capitalization of 32 billion USD (The Marijuana Index For Publicly Traded Companies n.d.). The worldwide market cap is $40.88 billion USD as of January 28, 2020 (Medical Marijuana Market Cap | MJNA n.d.).

As the increasing MC demand and economic and financial impact is contemplated, the importance of intellectual property rights (IPR) in this industry comes into focus. In this review article, the most important IPR instruments used in the MC industry are presented, accompanied by examples and data.

Intellectual property rights

The international framework for IPR

The World Trade Organization (WTO), founded in 1995, is the premier body regulating trade between nations and has enacted the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The TRIPS agreement provides benchmark standards for many types of intellectual property rights (IPR). IPR are those intangible rights owned and legally protected by a company or individual from outside use or implementation without consent. Intellectual property (IP) consists of patents, trade secrets, copyrights, know how, franchises, and trademarks. IPR are regarded as the transmission gear at the nexus of innovation, business, and law.

These types of IPR are most relevant to medical cannabis research:

Utility patents

Utility patents are an intellectual property right granted by a state within its territory to patent owner(s), excluding others from commercializing a technology recognized as novel and inventive claimed in the granted patent for a given time (up to 20 years with occasional judicial exceptions). Commercialization is defined as the commercial use, offer to use, sale, offer of sale, manufacture, or distribution of a patented technology or its products.

Plant breeders’ rights

IP instruments, known as Plant Variety Protection Rights (PVPR) or plant breeder’s rights (PBR), are an intellectual property right employed to protect commercialization of new varieties of cannabis plants developed by traditional breeding. A new cannabis variety unique in morphological characteristics may be protected using this IP instrument in most countries. To be eligible for a PBR, the new variety must be clearly distinguishable from any other commonly known variety and be sufficiently uniform and stable under cultivation.

Plant patents (USA)

An additional IPR protection for plant varieties, unique to the USA, termed a plant patent, exists. Plant patents extend the owner’s control and protection to asexual reproduction of a distinct and new variety of plant that expresses characteristics determined by its genotype. Plant patents can be granted for mutants (induced or spontaneous), hybrids, or transformed plants.

The exercise of IPR in the MC field incentivizes, accelerates, and rewards progress in this knowledge domain. Nations and regions all have their own particular histories and legacies entwined with ever changing social, economic, and cultural conditions. This influences local legislation on the scope and exploitation of IPR in MC.

Numerous articles have been published regarding cannabis plants and IPR but they are focused and localized to either a specific geographical territory (Rowand and Mcmahon 2018), a specific type of IPR (Jacobs 2017), specific fields in the cannabis plant industry (Flores-Sanchez and Ramos-Valdivia 2017; Gerra et al. 2010; Ranieri et al. 2016) or a specific species of Cannabis (Hahn 2019). Therefore, there is still a need for a broader analysis of IPR data concerning cannabis plants.

As the authors have noted, innovation in MC encompasses multiple activities in the journey from plant-to-drug. Therefore, it is not at all surprising that the relevant IPR instruments and policies are quite intricate, varied, and heterogenous, both regionally and nationally. In this study, we present IPR trends relevant to innovations in MC along the entire MC supply chain from upstream agritech (improved strains, genetic modification, plant material assessment, harvesting technology, and post-harvesting processing), midstream chemistry/analytics (extractions, purification methods, and separation methods), and downstream medical/biology (diseases, medical devices, compositions, formulations, and dosage forms). In this review, these categories will be applied. Furthermore, within this study, the researcher will be directed towards topics within IPR that bear consequences on MC research, including IPR-derived risks and limitations.

Materials and methods

Patent documents search

In order to find patent documents, the PatSnap search engine (https://www.patsnap.com/) was used. The search engine was instructed to return results from 116 national and regional databases (WIPO (WO)), Austria, Australia, Belgium, Benelux, Canada, Switzerland, Germany, Denmark, Spain, EUIPO, Finland, France, Great Britain, China Hong Kong, Ireland, Israel, India, China Macao, Netherlands, Norway, New Zealand, Poland, Russia, Sweden, Singapore, Thailand, China Taiwan, United Arab Emirates, Armenia, ARIPO, Argentina, Bosnia and Herzegovina, Bulgaria, Bahrain, Brunei Darussalam, Bolivia, Brazil, Belarus, Chile, Colombia, Costa Rica, Czech Slovak Rep., Cuba, Cyprus, Czech Republic, East Germany, Dominica Rep., Algeria, EAPO, Ecuador, Estonia, Egypt, GCC, Georgia, Greece, Guatemala, Honduras, Croatia, Hungary, Indonesia, Iceland, Italy, Jordan, Kenya, Kyrgyzstan, Cambodia, Kazakhstan, Lao People’s Democratic Republic, Lebanon, Lithuania, Luxembourg, Latvia, Morocco, Monaco, Moldova, Montenegro, The Republic of North Macedonia, Mongolia, Malta, Malawi, Mexico, Malaysia, Nicaragua, OAPI, Panama, Peru, Philippines, Portugal, Paraguay, Romania, Republic of Serbia, Saudi Arabia, Slovenia, Slovakia, San Marino, Soviet Union, El Salvador, Tajikistan, Tunisia, Turkey, Trinidad and Tobago, Ukraine, Uruguay, Uzbekistan, Venezuela, Vietnam, Yugoslavia, South Africa, Zambia, and Zimbabwe.

The IP searches mentioned in this publication were carried out as follows:

Search Searched publication section Keywords used Comments
Search A:
General search
Independent claims (cannab* OR marijuana) combined with International Patent Classification code A61 A61—medical or veterinary science; hygiene
Search B:
MC upstream technologies
Independent claims (cannab* OR marijuana) AND (cultivat* OR soil OR light OR water OR irrigat* OR planting OR selecting OR harvest OR post harvest OR packing OR storing OR storage OR curing OR drying OR pick OR pest OR herb OR ripen) combined with the International Patent Classification code A01 (excluding the A01H category which is inter alia, directed to ex planta technology). A patent or patent application was deemed a specific cannabis or marijuana upstream technology patent if the terms “cannabis or marijuana” appeared in the independent claim to the exclusion of other named plant species. 236 patent documents were returned by the search engine concerning the specific field of upstream MC technologies, representing 101 patent families. Manual inspection was carried out of at least one independent claim of each of the 101 patent families. 39 patents or patent applications were deemed, by the above criteria, to be specific MC upstream technology patents.
Search C:
MC upstream technologies
Independent claims (cannabinoid OR cannabis OR marijuana) AND (sensor OR sensing) AND (plant OR biomass OR harvest OR field OR greenhouse or hothouse) A patent or patent application was deemed a specific cannabis or marijuana upstream technology patent if the terms “cannabis or marijuana” appeared in the independent claim to the exclusion of other named plant species, and sensor or sensing, and plant or biomass or harvest or field or greenhouse or hothouse. Manual inspection was carried out of at least one independent claim of each of the 26 patent families. 6 patent families were identified in this way. Each was then compared to the results of the first search in order to eliminate double counting.
Search D:
MC upstream technologies—disease control
Title and abstract (cannabis OR marijuana) combined with International Patent Classification codes: (A01N OR A01N25 OR A01P OR A01P7). A01N—preservation of bodies of humans or animals or plants or parts thereof
A01N25—biocides, pest repellants or attractants, or plant growth regulators, characterized by their forms, or by their non-active ingredients or by their methods of application.
A01P—biocidal, pest repellant, pest attractant, or plant growth regulatory activity of chemical compounds or preparations
A01P7—arthropodicides
Search E:
MC upstream technologies—disease control
Independent claims (cannabis OR marijuana) combined with International Patent Classification codes: (A01N OR A01N25 OR A01P OR A01P7). A01N—preservation of bodies of humans or animals or plants or parts thereof
A01N25—biocides, pest repellants or attractants, or plant growth regulators, characterized by their forms, or by their non-active ingredients or by their methods of application
A01P—biocidal, pest repellant, pest attractant, or plant growth regulatory activity of chemical compounds or preparations
A01P7—arthropodicides
Search F: MC upstream technologies—in planta genetic modification technologies Title and abstract (cannabinoid AND (recombinant OR recomb* OR construct OR promoter OR vector OR genetically modified OR gm OR plasmid OR gene insertion OR insert OR gene editing OR crispr OR talens) OR (expression of cannabinoid) OR (biosynthesis of cannabinoid) combined with International Patent Classification codes: (C12N and/or A01H) for at least 4 iterations of IPC. C12N–M or enzymes, compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media
A01H—new plants or processes for obtaining them; plant reproduction by tissue culture techniques
Search G: MC midstream technologies Independent claims (cannabis OR marijuana) AND (extract* OR purif* OR separat* OR preserv*) AND (supercri* OR ultra* OR solvent).
Search H: MC downstream technologies Independent claims cannab* OR marijuana) AND (Alzheimer’s disease or appetite loss or cancer or Crohn’s disease OR celiac disease OR eating disorders OR anorexia OR bulimia nervosa OR epilepsy OR glaucoma OR anxiety OR schizophrenia OR posttraumatic stress disorder OR multiple sclerosis OR Parkinson’s disease OR tremor OR muscle spasms OR tooth decay OR dental caries OR nausea OR vomit* OR pain OR burns OR psoriasis OR cachexia OR inflammation) AND (composition OR compound OR formulation) AND (disease OR condition OR treatment OR therapy OR medic*) NOT synthetic) combined with International Patent Classification codes: A61 A61—medical or veterinary science; hygiene

PBR search

In order to find registrations of plant breeders’ rights, the Community Plant Variety Office (CPVO) database was used (https://cpvo.europa.eu/en). Under “variety finder,” Cannabis sativa was searched under the species Latin name. Only PBRs were selected with all types of applications being searched (including rejected, examined, and expired applications).

Generation of graphs, tables, and figures

PatSnap’s Insights analytical tool was used to generate patent graphics of filing rates, geographic territories, and assignee analysis. The Insights tool processes patent data to produce graphs and figures. The insights database selection tool is configured to inspect the 116 available databases listed above. Raw patent data was filtered by key word selection and International Patent Classification (IPC) selection. The search for most cited patent applications in the field of MC downstream technologies (Table 7) was based on the results of search H, with the table manually generated from data obtained by the Insights analytical tool.

Results

In order to search patent documents presented in this publication, the authors used the PatSnap search engine (see the “Materials and methods” section). Using broad keywords, approximately 2000 patent families directed to various MC technologies were found (see the “Materials and methods” section; search A).

Figure 1a shows the patent family filing rate rose over 6-fold, from approximately 60 filings in 2013 to 380 filings as of June 2020. The filings are concentrated in the USA (26.25%), Europe (12.26%), Canada (10.25%), and Australia (7.20%) with the remainder filed in other territories or at the intermediate international PCT (Patent Cooperation Treaty; WIPO) stage (Fig. 1b).

Overview on utility patents in the field of medical cannabis. a Graphically depicts the patent filing rate from 2001 to 2020. The total number of medical cannabis-related utility patents is represented in each column. b Graphical depiction of the main countries in which the MC-related utility patents were filed. The figures were generated using “Insights,” an analytic tool by Patsnap (https://www.patsnap.com). For more information on the PatSnap software operations, see the “Materials and methods” section

Upstream MC technologies

Upstream technologies are an important differentiator from traditional Pharma IP domains as these technologies are centered upon agricultural innovation. Before a cannabis product can be produced or even investigated as a medical candidate, strains must be selected, followed by the development and implementation of efficient cultivation methods. Companies that can repeatedly deliver high-quality harvests of appropriate plants with predictable yields and cannabinoid content will be at an advantage and protect their beneficial applied research by means of registered IPRs, namely plant breeders rights, plant patents, and utility patents.

Traditional breeding is increasing the production of Cannabis plants with unique traits. intellectual property rights to such plants are typically registered as PBR.

In order to characterize the cannabis-related PBR filings, a search was conducted for PBR registrations pertinent to Cannabis sativa (see “Materials and methods” section). Data obtained from the Community Plant Variety Office (CPVO) database, which includes the global figures, revealed 434 Cannabis sativa varieties applications. PBR filed in the European Union are the most numerous (48%), followed by Australia (8%), Russia (7%), and Canada (5.7%). The USA only has 4 listings, all approved in 2019. This is probably because, in the USA, it is only since 2019 that plant variety protection certificates under the International Union for the Protection of New Varieties of Plants (UPOV) are obtainable for new and distinct Cannabis sativa varieties with THC content not exceeding 0.3%.

As for plant patents, 30 cannabis plant patents and applications have been filed in the USA. The first cannabis plant patent USPP27475 (Cannabis plant named “Ecuadorian Sativa” (USPP27475P2 – Cannabis plant named ‘Ecuadorian Sativa’ – Google Patents n.d.)) was granted in 2016 to Kubby Patent and Licenses LLC. Recently, the Biotech Institute LLC was granted US Plant Patent USPP31535 for their “Lemon Crush OG” (USPP31535P3 – Cannabis plant named ‘LEMON CRUSH OG’ – Google Patents n.d.) cultivar.

From the data revealed in the above searches, it can be seen that researchers are exploiting the relatively low technological barrier needed to qualify for PBR or Plant Patent protection. They do this by protecting varieties for morphological trait uniqueness (as required by the authorities), while in practice protecting the therapeutic or pharmacological value of their plant variety.

As for MC utility patents focused on upstream technologies, 236 patent documents were found (see the “Materials and methods” section; search B), representing 101 patent families. Following a manual inspection, 39 patents or patent applications were deemed by the criteria described in the “Materials and methods” section to be specific MC upstream technology patents.

To cover additional areas in this specific field, mainly sensing monitoring in greenhouses, a second search was carried out (see the “Materials and methods” section; search C). Fifty-two patent documents were returned by the search engine, representing 26 patent families. Following a manual screening, 4 patent families were identified. Overall, it was determined that there were 43 independent upstream specific MC upstream technology patents.

The MC upstream technology patent data reveals IPR activity in the following areas: seed and crop protection, cultivation methods and equipment, precise crop harvesting in situ, post-harvest methods, genetic engineering technologies, and disease and pest control.

Representative patent applications of the first four topics are described in Table 1.

Table 1 indicates 4 patents specifically directed to cannabis cultivation although most of the patents in the cultivation and equipment area are controlled growth and seed technologies applicable to many plant species, including cannabis. Two patents were identified directed to harvesting methods for cannabis plants in situ.

An additional patent search was carried out specifically for controlling diseases and pests to which the cannabis plant grown as a crop is particularly prone (see the “Materials and methods” section; search D). This search results in 131 patent documents, grouped into 86 patent families. Several examples for patent documents concerning controlling plant diseases, including cannabis, are detailed and shown in Table 2.

When a further, more limiting search was carried out in the context of disease control in cannabis plants, this time including cannabis or marijuana in “independent claims” and not in the “Title and abstract” of the patent documents (see the “Materials and methods” section; search E), 21 documents were retrieved. Manual inspection of the relevant texts revealed that these were patents providing solutions targeting a number of plant species, cannabis merely being among the claimed species.

From these data, MC researchers may note that protecting and controlling cannabis plant diseases by biological or eco-friendly non-hazardous compounds or materials would appear to be an area worth innovating and patenting in order to achieve cannabis-specific patentable technology and enhance the MC infrastructure.

A major finding of this present study is the large amount of patent data on ex planta (Table 3) and in planta (Table 4) genetic modification technologies (see search F in the “Materials and methods” section), including production of cannabinoids from microorganisms, suspended plant cells, and recombinant DNA technologies (genetic modification, expression of new genes, gene silencing, gene editing, new trait selection methods, and novel breeding processes). As more MC products of genetically manipulated origin becomes available, it is likely to influence the perception of MC in some circles as a natural herbal product.

In conclusion, the topics in this particular field vary but there appears to be room for research intervention upstream because absolute numbers of patents are low and many of the patents are not specific to particular cannabis-related problems. Additionally, new strains, traits, and genetic manipulations and editing are advancing, which may affect the discourse around MC.

Midstream technologies

The major patenting activity in this part of the supply chain is still in natural product technology, namely extraction of cannabinoids, terpenes, and flavonoids as well as purification, separation, and preservation methods. The challenge here is to provide easily scalable extraction methods with a high yield of the desired compounds, chiefly the non-psychotropic ingredient CBD. Other potentially medically useful compounds, referred to as “entourage” compounds, are present in low concentrations in the natural state and require the development of meticulous extraction, separation, and purification techniques. A specialized patent search was performed as described in the “Materials and methods” section (search G).

Figure 2 illustrates over 200 filings in this field since 2015 whereas, prior to that year, the commercial (and patenting) interest in extraction methods from cannabis plants was close to negligible. There are several extraction methods being patented, including ultrasonic disruption, electroporation, and organic solvent extractions, but since 2013, the patent activity has been mainly dominated by supercritical gas extraction methods. GW Pharmaceuticals, a market leader in medical cannabis technologies, is a holder of several patents in this latter technology. Table 5 presents a few examples for such patent applications.

Patent filing trend in the field of midstream medical cannabis technologies. Graphical depiction of the number of patents concerning midstream medical cannabis technologies filed from 2001 to 2020. The figure was generated using “Insights,” an analytic tool by PatSnap (https://www.patsnap.com). For more information on the PatSnap software operations, see the “Materials and methods” section

Downstream technologies

Medical cannabis extractions obtained from midstream technologies are formed into compositions, formulations, and compounds for which patent protection is sought in regard to the treatment of a number of medical conditions. These indications have been associated with MC treatment and include Alzheimer’s disease; appetite loss; cancer; Crohn’s disease; celiac disease; eating disorders such as anorexia and bulimia nervosa; epilepsy; glaucoma; mental health conditions such as anxiety, schizophrenia, and posttraumatic stress disorder; multiple sclerosis; Parkinson’s disease; tremor; muscle spasms; tooth decay or dental caries; nausea and vomiting caused by chemotherapy; pain; burns; psoriasis; cachexia; and inflammation. Therefore, a patent search for MC downstream technologies related specifically to the above medical conditions was carried out (see “Materials and methods” section, search H).

Approximately 570 patent families (2200 patent documents) have been filed in these downstream technologies, with the filing rate rising steadily since 2011–2013 (Fig. 3a). The steep increase in patent filing and grants (Fig. 3a and b) since 2011–2013 is consistent with the recognition by industry that the number of US states allowing legal medical cannabis was reaching a critical number. In many other countries, by this time, legalization and medical opinion had progressed towards the medicalization of cannabis and the liberalization of its use.

Patent filing trend in the field of downstream medical cannabis technologies. a Graphical depiction of the number of patents concerning downstream medical cannabis technologies filed from 2001 to 2020. b Graphical depiction of the number of patents that were granted through 2001–2020. The figures were generated using “Insights,” an analytic tool by PatSnap (https://www.patsnap.com). For more information on the PatSnap software operations, see the “Materials and methods” section

Additionally, it can be seen in Fig. 4, which depicts the national and regional patent filing trends in the field of MC downstream innovations, that the USA, followed by China and the European countries, outstrip all other territories as a market and originator of these technologies.

Main countries in which patents related to downstream medical cannabis technologies were filed. Graphical depiction of the number of patents concerning downstream medical cannabis technologies filed from 2001 to 2020 and the main countries in which these patents were filed. The figure was generated using “Insights,” an analytic tool by PatSnap (https://www.patsnap.com). For more information on the PatSnap software operations, see the “Materials and methods” section

In industries driven by innovation, it is crucial for companies to continuously construct and defend a patent portfolio commensurate with the core proprietary technologies upon which their commercial well-being depends. The company patent portfolio should also include technologies that may be contemplated by their competitors so as to exclude them from the market, at least for a time. Figure 5a lists the top 10 patent assignees in the field of downstream MC technologies. GW Pharmaceuticals is a company, which on the evidence of their patent filing, market, and financial data implements patent strategies successfully. It will be noted that Yissum Research development is the technology transfer company of the Hebrew University of Jerusalem, Israel. So, their motivation for holding a substantial patent portfolio relevant to medical cannabis is for licensing purposes and/or for supporting tech incubator companies. Other companies, such as Zelda Therapeutics (currently known as Zelira Therapeutics Ltd), Cannabics Pharma, and Axim® Biotechnologies Inc., will find their patent portfolios tempting to future partners and investors or serving as assets that may be sold or licensed for royalties.

Main patent assignees and markets of patents related to downstream medical cannabis technologies were filed. a Graphical depiction of the main assignees in the field of downstream medical cannabis technologies and the number of patent applications they own. b Graphical depiction the concentration of the main patent assignees from 2001 to 2020. The figures were generated using “Insights,” an analytic tool by PatSnap (https://www.patsnap.com). For more information on the PatSnap software operations, see the “Materials and methods” section

The most dominant assignee is GW Pharmaceuticals and its subsidiary GW Research, which together hold about 80 patents in this MC-related field. Interestingly, we can observe that, in spite of GW’s ownership of a large group of patents, the overall patent monopolization in the field has been on a downward trend. This is signified by the decreased ratio of the number of patents of the top 10 assignees relative to the total number of applications when compared to the ratio found in the early 2000s (Fig. 5b). This observation is a characteristic of a nascent industry and is evidence of the rapid formation of new companies and startups in recent years creating their own patent eligible technologies.

Moreover, in the last 5 years (2016–2020), companies such as Buzzelet (presently Bazelet) and Radient Technologies have been resurfaced and also filed patent applications. Such companies provide a burgeoning source of new innovation and monetizable patents. They are often regarded as potential partners to companies with complementary technologies or acquisition targets for bigger companies or competitors.

An analysis of the origin and patent protection of the technology field in Europe, China, Japan, Korea, and the USA reveals that companies typically seek to protect their inventions in their own local market and are possibly overlooking potentially profitable markets elsewhere as legislation continues to liberalize.

Innovations directed to medical conditions

An obvious trend observed among the resulting patent literature was related to MC modes of delivery. Various modes of delivery are used and patented to administer cannabinoid formulations and compositions to the patient, such as transdermal, topical, oral, buccal, sublingual, and rectal. Medical cannabis compounds may be smoked or inhaled. Medical cannabis can be in edible form, capsules, tablets, pills, ampoules, oils, waxes, liposomes, particles, suspensions, cartridges, droppers, micelles, pastes, and more. Table 6 depicts several patent applications in the field of downstream MC for the treatment of various medical conditions in humans and in other animals.

All of the patents and patent applications mentioned above, as well as the rest of the data mentioned in this article, are at various stages of the patent process, chiefly examination or grant. In order for a patent to proceed to grant, the patent examiner must be satisfied that the patent application is new and inventive. The examiner will endeavor to provide “prior art” (publicly available literature published before the date of the patent application) citations to challenge the novelty and inventive step of the patent application. Table 7 provides data on patents most cited by patent examiners during examinations of subsequent patent applications relevant to the application in question. Such patents therefore represent prior art and may be considered barriers to patentability, possibly even restricting “freedom to operate,” the legal operating space available to researchers which is unoccupied by pre-existing valid patents.

The authors have researched the most cited patents wielded by patent examiners against patent applications in the downstream category. Some of the most cited patents presented in Table 7 are not necessarily from downstream categories themselves, yet have been cited by the examiner during examination. It is often the case that, quite legitimately, the examiner will cite from any document felt to have a bearing on patentability even if the citations were not from the same patent category. It can be observed that, in the downstream medical cannabis arena, the data shows that most of the key cited patents have expired. Therefore, while the expired patents noted in Table 7 do not restrict freedom to operate, they may hamper patentability due to prior art issues (novelty or inventiveness).

The technology fields are still rather open to patent competition. Within the top patent holders, and the newly formed companies, there are no great conglomerates of patents. This bodes well for researchers and investors alike who may see opportunities, given the patent filing trends shown in the figures.

A useful way of classifying technology fields within medical cannabis is to use the WIPO authorized International Patent Classification (IPC) hierarchical system. The IPC provides language-independent symbols to designate patented technology within a field. This tool has been used to generate Table 8, showing the number of patents accumulated in each designated technology area within the domain of medical cannabis. It can be seen that there are over 250 patents directed towards preparations and carriers (the A61K classified groups) and approximately 150 patents directed towards various medical conditions and indications (the A61P classified groups).

In spite of the large number of patentable innovations in various disease conditions as reported above, disappointingly, few cannabinoid drugs have been granted marketing approval by authorities such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These approved drugs are presented in Table 9.

Exemptions in patent law affecting research in medical cannabis

Medical cannabis research is a very often applied research with commercialization as the ultimate goal. Therefore, it is essential for MC researchers to consider the potential of patent law to block a research program whether the researchers are affiliated to academia, research institutions, companies, or collaborations.

The exclusive rights conferred to the owner of a patent are wide in scope to incentivize investment in useful technological advance for the benefit of society as a whole. Comprehensive enforcement of these IPR without exception may not always serve the best interests of the public. A need to balance between the rights of the patent owner and the broader interests of society is recognized by most national governments. In national jurisdictions and regional authorities, laws, regulations, and practices are enacted to provide exceptions and safe harbors to the maximal patent exclusivity right (Experts’ Study on Exclusions from Patentable Subject Matter and Exceptions and Limitations to the Rights n.d.). Among these exceptions are (i) private and/or non-commercial use, (ii) experimental use and/or scientific research, (iii) extemporaneous preparation of medicines, (iv) prior use, (vi) acts for obtaining regulatory approval from authorities, (vii) exhaustion of patent rights, (viii) compulsory licensing and/or government use, and (ix) certain use of patented inventions by farmers and breeders.

Likely to be pertinent to the MC researchers are research exemptions or safe harbor exemptions to the rights conferred by patents, particularly in the case of drugs where regulatory or marketing approval is sought. In the USA, these exemptions are called the § 271(e)(1) exemptions or Hatch-Waxman exemptions, but in many countries they are referred to as Bolar provisions (Roche Products, Inc. Appellant, v. Bolar Pharmaceutical Co., Inc., Appellee, 733 F.2d 858 (Fed. Cir. 1984) : Justia n.d.).

Many nations have similar exemptions in place of varying nature and scope. For example, India clearly and broadly provides Bolar type exemptions for research under Section 107A of the Indian Patent Act.

In the European Union, Bolar equivalent exemptions are allowed under the terms of EC Directives 2001/82/EC (as amended by Directive 2004/28/EC) and 2001/83/EC (as amended by Directives 2002/98/EC, 2003/63/EC, 2004/24/EC and 2004/27/EC).

A comparative study of patent law (Jaenichen and Pitz 2015) determined that Great Britain, France, Spain, Italy, Germany, and the Netherlands do not extend patent rights to studies and trials necessary for obtaining drug approval for the marketing of a drug. In Great Britain, it has not been settled whether the patented product used as a tool during a process for obtaining regulatory approval is exempt.

In the USA, exemptions from patent enforcement rights exist when the research using the patented product is done in order to obtain regulatory approvals for use, manufacturing, or marketing approvals (Russo and Johnson 2015).

In Eli Lilly and Co. v. Medtronic, 496 US 661 (1990) (Lilly, and Co. v. Medtronic, Inc. :: 496 U.S. 661 (1990) :Justia US Supreme Court Center n.d.), the US Supreme Court held that the exemption also applies to medical devices, an interesting decision that affects cannabis delivery devices.

University researchers should also note well that experimentation by universities and not-for-profit-organizations using patented products may not be exempt even if the intention is not directly commercial. The university’s experiments may result in publications advancing the prestige of the university or its researchers, possibly attracting funds and students, which constitutes furtherance of a business activity. As a consequence, the research is prohibited (Cai 2004).

In light of the above, researchers in medical cannabis should note that patent law allows sufficient room for research activities to promote innovation (Jaenichen and Pitz 2015), but academic researchers must be aware of potential pitfalls, particularly in light of the restrictions to ostensibly academic research at research institutes in the USA.

Medical cannabis patent litigation and freedom to operate

To date, there has been little litigation concerning patent infringement, probably because of relatively recent acquisition of IPR concerning MC research, but this trend is likely to change. Patented CRISPR technology is increasingly used to edit plant genes without inserting foreign genetic material. Patents for gene editing in plants are an established feature of the plant innovation landscape. These gene editing patents often cover a wide variety of plants or are general to all plants including Cannabis. Two examples of patents potentially limiting to gene editing in Cannabis are further detailed in Table 10.

US patent 9957515 to Cibus claims use of a gene repair oligonucleotide or “GRON” when introduced into any plant cell when used with a CRISPR. Another CIBUS patent, US10287594, covers use of the GRON in combination with other strand breaking gene editing elements as well as CRISPR. When contemplating using gene editing, it is advisable for applied researchers in MC to be well acquainted with such patents that may block or limit their patentability in MC or limit the freedom to operate of an applied MC researcher.

It is clear from the presented patent data that much of the patenting activity has been focused on the downstream product segment. It is in this segment that the first patent litigation conflicts have arisen. Such litigation signals clearly to the MC researchers that patent holders value patents in this field and, through the agency of patent law, are willing to prevent competitor researchers from utilizing patented technology without consent of the patent holder. Patents are also opposed by competitors to increase the freedom of their MC researchers to operate.

The most notable cases so far are the GW pharmaceuticals case litigated at the United States Patent and Trademark Office (USPTO) and the United Cannabis Corporation Case, which was litigated at the United States District Court for the District of Colorado (see Table 11).

GW Pharmaceuticals v. INSYS Therapeutics

In this case, US patent No. US9066920 (US9066920B2 – Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy – Google Patents n.d.) belonging to GW Pharmaceuticals was subject to a patentability challenge by INSYS Therapeutics. This patent is one that potentially protects GW’s FDA approved Epidiolex (CBD) for epilepsy.

The grounds for invalidation asserted by INSYS before the USPTO Patent Trial and Appeal Board (PTAB) were essentially obviousness. INSYS complained that previous publications provided sufficient guidance to an expert in the field in order to obtain the claimed invention, namely that CBD of plant origin of a given dosage was effective against certain types of epilepsy and that this was therefore too obvious to deserve patent protection. Although claims 1 and 2 were invalidated in the proceedings, the PTAB found the essence of the patent (recited in the remaining claims) to be sound and thus assertable against an infringer.

The authors comment that this case demonstrates the importance of obtaining a patent as part of an overall business strategy. Although it took about 6 years for GW pharmaceuticals to obtain the patent and FDA approval was only granted in 2018, the patent will be valid for another 12 years at time of writing, providing GW with monopoly rights. The first external challenge to the patent was beaten off such that interested parties will comprehend the value of such a patent in a medical cannabis IP and product portfolio.

UCANN v. Pure Hemp Collective

Another example heralding the importance of patents in this high-value area is the case of United Cannabis Corporation (“UCANN”), which, in 2018, sued Pure Hemp Collective Inc. (“Pure Hemp”) in the United States District Court for the District of Colorado (United Cannabis Corporation v. Pure Hemp Collective, Inc. (Case No.: 1:18-cv-01922-NYW) (United Cannabis Corporation v. Pure Hemp Collective Inc., 1:18-cv-01922 n.d.) for patent infringement. UCANN found a similar product allegedly within the scope of their granted claims in terms of concentrations. Here, the defendant Pure Hemp asserted that the specification of UCANN’s patent was not sufficiently clear as to define the boundary of the claim. Judge Martinez then directed the parties to obtain a summary judgment as to the indefiniteness issue in the claims. At the time of writing, the issue has not been settled but few can doubt that it was important for UCANN to file the patent. At the very least, the contentiousness of the patent and court proceedings must be expensively distracting to UCANN’s competitor while UCANN gains traction in the market. These two cases illustrate the value to researchers of obtaining a more than superficial knowledge of patents in the MC field.

Indigenous Property Rights, traditional knowledge, and cannabis IPRs

The Scottish physician W.B. O’Shaunghnessy can be said to have introduced cannabis to Western medicine in 1841 after observing its use in India and carrying out animal trials prior to treating patients. In cultures and countries as varied as China, India, Zimbabwe, South Africa, Brazil, and Jamaica, traditional medical uses of cannabis include menstrual fatigue, gout, rheumatism, constipation, anesthesia, bronchitis, asthma, diabetes, anthrax, malaria, blackwater fever, blood poisoning, dysentery, glaucoma, diarrhea, fever, burns, abrasions, and wasting disease. It can be thus said that the contributions of modern researchers are, to an extent, built upon contributions of traditional non-western cultures and their ancestors (Spicer 2002).

The data presented in the previous sections attests to the very recent commercial medicalization of cannabis, but medical and therapeutic cannabis has a very long history. Indigenous and local peoples of many countries and regions have been preparing traditional cannabis remedies and selecting and stewarding local landraces, cultivars, and varieties of cannabis plants for centuries (Duvall 2016). Geographically and culturally isolated gene pools were blended in unprecedented combinations to develop both industrial hemp and recreational/medicinal Cannabis cultivars that would be productive when grown in environments to which they were adapted. Human selection has increased seed and fiber yield and quality as well as altered cannabinoid profiles.

Local and indigenous farmers, as well as communities, in developing and emerging regions that traditionally grew Cannabis have valued it in their cultures and made the herb popular in the first place. These farmers must be safeguarded against being excluded from rewards and economic opportunities now flowing towards the burgeoning developed world industrialization of medical cannabis. The above-mentioned conventional IPR (patents and PBR) work in favor of modern-day research in the developed world and offer little or no protection to the indigenous stakeholders. Examples of plants long known by indigenous peoples and nurtured and stewarded by them whose natural qualities are not guaranteed by patent law are shown in Table 12. These examples reveal that the patent system is inadequate for ensuring rights to Indigenous Peoples. Accordingly, it would be desirable to protect the rights of these peoples in the rush to patent medical cannabis research. There is a growing demand for industry to share some of its rewards with the traditional knowledge custodians and practitioners that provided the building blocks of medical cannabis knowledge to the medical cannabis researcher. What is being done to ensure that traditional knowledge (TK) owners will be rewarded for their stewardship, nurturing, and knowledge, passed down through the generations? Commercial breeders may use traditional farmers as a source of cannabis to produce advantageous hybrids, which then may be protected by Plant patents or PBR. Other commercially useful patent-protected cultivation methods or extraction methods or medical uses may have partial origins in TK of a particular Indigenous People.

In order to provide resolution platforms for these matters, there are some internationally agreed legal instruments available; the 2014 Nagoya protocol is a supplementary agreement to the Convention on Biological Diversity (CBDR) of 1992 (Smith et al. 2018). It provides a means by which fair distribution of benefit and fair access can be allotted to Indigenous Peoples and other custodians of traditional knowledge and germplasm. Although not an IPR for rewarding innovation as such, rights conferred by CBDR/Nagoya fulfil an IPR function for the custodianship and curation of important plant species that are so fundamental to all agriculture, including C. Sativa. There is every reason to expect that such a “quasi IPR” will be relevant to cannabis since obligations under the Nagoya Protocol apply to the use of genetic resources and traditional knowledge. Uses of resources and TK are defined as research, development, innovation, pre-commercialization, or commercialization as well as the benefits arising from their utilization. Contracting parties are obliged to take measures in relation to access to genetic resources, benefit-sharing, and compliance.

The protocol includes prior informed consent (PIC) procedures between traditional knowledge providers and companies, mutually agreed terms (MAT), access permits, and benefit-sharing obligations, whether monetary or non-monetary (royalties and the sharing of research data). These obligations are harmonized with the domestic legislation or regulatory requirements of the contracting party providing genetic resources. A permit is issued when access is granted by administration of the Access and Benefit Sharing Clearing House (ABCH). Compliance is acknowledged by an Internationally Recognized Certificates of Compliance (IRCC) as voucher evidence that the accessed genetic resources or traditional knowledge have appropriate PIC and MAT in accordance with the Access and Benefit Sharing (ABS) requirements of the provider country.

It is not difficult to foresee that the evolution of instruments such as the Nagoya Protocol with future modifications will have a serious role to play in the multinational and multicultural relationships that are forming around medical cannabis commercialization and IPR rights. The authors foresee that research organizations, institutions, and companies with a stake in medical cannabis will incorporate compliance with the Nagoya Protocol and similar ABS regulations into the standard IPR due diligence process for commercial risk mitigation before committing resources into research and development of medical cannabis products.

Conclusions

In this review of IPR data, we have presented characteristics of intellectual property landscape of the medical cannabis field. IPR data is distributed along the entire MC supply chain, following the upstream–midstream–downstream paradigm.

Agri-technology specific to the cultivation of cannabis plants is not well covered, opening up much scope for research in this area. Work has been reported on genetic manipulation of the cannabis plant, which is likely to have an impact on the discourse framed around MC as a natural herbal therapeutic. Patents directed to gene editing in cannabis are making their appearance in the literature. It is likely that researchers in this field will have to be wary of the contentiousness of patent holders of CRISPR/Cas9 system patents in their attempt to prevent freedom to operate blocks to their research.

In contrast, traditional variety development has led to over 300 protected cannabis varieties according to observed PBR and Plant Patent data. It is to be expected that more variety registrations and plant patents will be granted in the USA as a result of continuing legislative changes easing the path of this branch of MC research.

Remote monitoring and analysis of cannabinoid content, biological control of cannabis plants, successful endogenous, and exogenous expression of cannabinoids in cannabis plant cells have not been convincingly reported although progress has been made using yeast and other cell expression systems. Biosynthetic production of cannabinoids by exploiting enzymes of the cannabinoid metabolic pathways has been reported, with several extraction methods having been claimed. These too are all areas that certainly warrant further research.

Although IPR (especially patents) in the upstream and midstream technologies are not as numerous as other equivalent fields in agritech, approximately ten-fold more patents have been filed in the downstream therapeutic sector. Medical cannabis products cannot be successfully and efficiently generated without full knowledge and development of upstream–midstream processes required to provide characterization and consistency of the downstream product or drug. This may well explain why, although a large group of patent families exist encompassing various medical indications, only three cannabis derived drugs, Epidiolex, Sativex, and synthetic Syndros (liquid formulation of THC), have received FDA marketing approval. The broad implications to downstream research are that upstream and midstream research must be bolstered and the number, quality, and depth of clinical trials and clinical research should be increased. The patent review data supports the notion that multidisciplinary discourse between researchers along the entire supply chain is likely to yield fruitful results.

There is much opportunity for research but researchers should be aware of the potential risks and challenges that patents pose to inventors. Two contentious patent cases are reported, which no doubt herald future infringement and invalidation challenges to claimed IPR in this industry. Such cases are important since they reinforce to researchers the importance of obtaining and defending patents and maintaining hard won priority advantages.

The authors predict that IPR scenarios in medical cannabis will be further enriched by the emergence of international and national “quasi – IPR” in the form of the CBDR, Nagoya protocol, and other arrangements to facilitate research partnerships between multidisciplinary departments in academia, industry, emerging nations, and local and Indigenous Peoples.

Our review provides evidence that an understanding of the pertinent IPR environment is essential for MC researchers to (i) minimize risks of having their work hindered, halted, or made irrelevant and (ii) recognize research opportunities of unfulfilled needs.

Availability of data and materials

The datasets used and analyzed in this review article are available from the corresponding author upon reasonable request.

Marijuana Giant Canopy Growth Claims Ownership Of Oil Extraction Technology And Sues GW Pharma For Patent Infringement

Cannabis oil is the viscous, sticky, THC or CBD-rich sludge found in popular vaporizer pens and oil cartridges. To make cannabis oil, processes using liquid carbon dioxide to extract the active ingredients from the plant material is one of the most popular techniques.

And anyone using a particular CO2 extraction method is using technology owned by Canadian cannabis giant Canopy Growth and potentially owes them money, the company claims in a recently acquired US patent and in a potentially blockbuster lawsuit filed on Tuesday.

Sativex, a cannabinoid-medicine made by British firm GW Pharmaceuticals. The company’s extraction . [+] method is the intellectual property of a Canadian company called Canopy Growth, that firm claimed in a lawsuit filed Tuesday.

Universal Images Group via Getty Images

News of the lawsuit was first reported Wednesday by Marijuana Moment.

If Canopy Growth prevails in its suit against GW Pharmaceuticals, the wildly successful UK-based firm that manufactures and markets Epidiolex, a CBD-based prescription drug available for more than $1,200 a bottle, the implications for the recreational cannabis industry in the US, as well as the global CBD business, are immense.

After obtaining a ruling that GW Pharmaceuticals used its intellectual property to extract CBD into Epidiolex, Canopy would be in a strong position to claim further patent infringement—including against almost every major cannabis-oil manufacturer in the United States, multiple experts said Wednesday.

The Making Of New York’s $150 Million ‘Cannabis Campus’

Blackstone To Sell The Cosmopolitan Of Las Vegas For $5.65 Billion

The Feds Are Coming For Delta-8 THC

The patent “really broadly covers CO2 extraction, which is the most widely used, and perhaps most important extraction technique,” said Larry Sandell, a Washington-DC patent attorney who is not involved in the lawsuit.

“I don’t know how much CO2 extraction falls outside the scope of the patent’s claims,” he added. “This is why people should care.”

“Potentially, everybody who does CO2 extraction may be infringing.”

EVERGREEN, CO – APRIL 18: Sean Conrad, lead process development in production and chemistry for . [+] Ebbu, works on the NovaSet machine inside the company’s purification lab on April 18, 2018 in Evergreen, Colorado. Canopy Growth also obtained this company’s intellectual property.

Denver Post via Getty Images

Canopy Growth did not immediately respond to a phone message and an email seeking comment on Wednesday.

In an email, a spokesperson for GW Pharmaceuticals said the company was aware of the suit but would not comment on pending litigation.

The value of shares in GW Pharmaceuticals, traded on NASDAQ, dropped about 3.5 percent on Tuesday, to $118.43.

Shares in Canopy, also traded on NASDAQ, increased about 4.5 percent to $27.01.

To prevail, Canopy will have to prove that its patent is the first recorded example of the use of the technology described.

For GW Pharmaceuticals to win, the company will have to demonstrate that its method, described in broad terms on its website, uses technology not claimed in Canopy’s patent—or that the technology that Canopy’s new patent claims were “known or obvious” in 2000, when the patent application was filed.

The list of potential cannabis companies who could be on the hook to Canopy for a licensing fee or other damages is vast. It includes just about anyone making CBD oil, which is legal in all 50 states, as well as THC oil for the multi-billion-dollar recreational cannabis market, experts contacted for this article said.

“Given that the patent in question is part of a patent family dating back more than twenty years to October 2000, it stands to reason that a significant portion of cannabis companies use Canopy’s extraction process to produce CBD,” said Meital Manzuri, a Los Angeles-based cannabis law attorney familiar with industry technology patents.

Canopy is one of the biggest players in legal cannabis in Canada, and has made significant steps to expand to the United States.

Beverage giant Constellation Brands, which owns many popular alcohol brands, has invested billions into the company beginning in 2018.

Canopy also boasts a global CBD business, including one line of CBD products marketed under the Martha Stewart brand name.

Earlier this month, on Dec. 4, Canopy obtained the rights to a nearly 20-year-old patent application filed by a German company called Spectrum Therapeutics, public records show.

According to a document filed with the US Patent Office, Canopy paid $1 for the technology, plus “other good and valuable consideration, monetary and non monetary.”

On Tuesday, the US Patent Office issued Canopy the patent, for a “Process For Producing An Extract Containing Tetrahydrocannabinol And Cannabidiol From Cannabis Plant Material, And Cannabis Extracts,” records show.

The patent application, first filed by an inventor named Adam Mueller in October 2000, describes broadly the process of using CO2 at “subcritical” temperatures to extract THC and CBD from raw cannabis flower.

On the same day Canopy received the patent, the company filed a patent lawsuit in federal court in Waco, Texas.

The timing suggests Canopy had the lawsuit ready, and may have obtained the patent with the specific intent to file such a potentially industry-disrupting lawsuit, experts contacted for this article said.

In the lawsuit, Canopy states that Mueller’s extraction method, described in the October 2000 patent filing, is the same method that GW Pharmaceuticals describes as part of the Epidiolex manufacturing process on its website.

According to the suit, GW Pharmaceuticals had to have been aware of the earlier patent filing, since, as Canopy claims, GW Pharmaceuticals tried to license it. Instead, “in 2017, GW declined a license” for the patent, the suit claims.

“This case is not about restricting patient access to Epidiolex,” the suit claims. “Rather, Canopy brings this action to put a stop to GW’s knowing and unauthorized use of Canopy’s intellectual property.”

To use the patent to sue GW Pharmaceuticals—technically a cannabis company but as a pharmaceutical company that makes a CBD-based medicine, a more stable investment—rather than a smaller competitor in the commercial recreational cannabis space is a bold choice.

It suggests that Canopy could be preparing to enter the global CBD-based medicine game, said Avis Bulbulyan, a Los Angeles-based cannabis consultant who sits on a committee that advises the California state Bureau of Cannabis Control, which regulates in the industry in that state.

It could also mean that Canopy is serious about competing with GW Pharmaceuticals. Or it could be a very strategic play to own a piece of almost every existing cannabis company.

“I don’t think it’s a quick money grab,” he said. “If it was, Canopy would try to pick off a smaller competitor rather than go against a giant like GW Pharma.”

“And if GW Pharma settles or loses,” he added, “everybody’s fair game at that point.”